Expert Opin Biol Ther 2012;12:37-51
Regulatory and safety status: TA-1 is pending FDA review and not currently approved for use in humans
we're a team of specialists deeply invested in the integrity of research
Noticeable hair lossshedding more than 125 hairs per day, thinning hair in certain areas only, or a generally less active growing phaseare all associated with menopause
Thereby, it is important to indicate that with consistently less nerve damage in all damaged areas in all BPC 157-cuprizone rats, the most important evidence is the consistent beneficial effect of BPC 157 also in those areas that were most affected, and thereby markedly improved gross presentation and functions in BPC 157 rats
By rapidly recruiting alternative pathways around occluded vessels, BPC-157 addresses the consequences of thrombosis without necessarily dissolving the clot itself